JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil
25. april 2026 opdateret af: heba ahmed abdelgayed ibrahim, Kasr El Aini Hospital
Assessment of Janus Kinase 2 Expression in Patients With Androgenic Alopecia and Its Modulation by Topical Minoxidil Therapy.
Androgenetic alopecia is a common form of progressive hair loss.
This prospective single-arm pre-post interventional study aims to assess tissue Janus Kinase 2 (JAK2) expression in patients with androgenetic alopecia by comparing balding and non-balding scalp at baseline, and to evaluate changes in JAK2 expression in balding scalp after 3 months of topical minoxidil 5% therapy.
Clinical response will be assessed using standardized trichoscopic parameters.
Studieoversigt
Status
Rekruttering
Betingelser
Detaljeret beskrivelse
This study will recruit 25 adult patients aged 18 to 50 years with mild to moderate androgenetic alopecia attending the Dermatology outpatient clinic, Cairo University Hospital.
At baseline, participants will undergo clinical evaluation, standardized photography, and trichoscopic assessment.
Three 2 mm scalp punch biopsies will be obtained over the course of the study: one from the balding scalp area and one from the non-balding scalp area at baseline, and one from the balding area after 3 months of therapy.
Tissue JAK2 protein levels will be measured by ELISA.
Participants will receive topical minoxidil 5% solution for 3 months (1 cc twice daily for men and once daily for women).
The primary endpoint is the comparison of tissue JAK2 levels between balding and non-balding scalp at baseline.
Secondary analyses will assess change in JAK2 levels after treatment and correlations with clinical improvement by trichoscopy.
Undersøgelsestype
Interventionel
Tilmelding (Anslået)
25
Fase
- Ikke anvendelig
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Heba Ahmed
- Telefonnummer: +201016532351
- E-mail: heba.a.abdelgayed@kasralainy.edu.eg
Studiesteder
-
-
Cairo Governorate
-
Cairo, Cairo Governorate, Egypten, 11555
- Rekruttering
- Kasr El Aini Hospital
-
Kontakt:
- Heba Ahmed, Lecturer of Dermatology
- Telefonnummer: +201016532351
- E-mail: drhebaahmedyt@gmail.com
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
Tager imod sunde frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Male adults aged 18 to 50 years with androgenetic alopecia.
- Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V.
- Patients who are treatment-naive or willing to undergo an adequate washout period for prior hair loss therapies of at least 1 month.
- Willing and able to provide written informed consent.
Exclusion Criteria:
- Other types of hair loss, including inflammatory or scarring alopecia.
- Inflammatory scalp dermatoses, such as psoriasis or seborrheic dermatitis.
- Use of systemic immunosuppressants, JAK inhibitors, or systemic corticosteroids within the last 12 months.
- History of severe systemic disease, including renal, cardiovascular, or hepatic disease.
- Chemotherapy during the last 5 years.
- Bleeding disorders.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Topical Minoxidil 5% With Scalp Biopsy and JAK2 Assessment
Participants with androgenetic alopecia will undergo baseline clinical and trichoscopic assessment, baseline 2 mm punch scalp biopsies from balding and non-balding areas for tissue JAK2 protein measurement by ELISA, treatment with topical minoxidil 5% for 12 weeks, and a repeat 2 mm punch biopsy from the balding scalp after treatment for repeat JAK2 assessment.
|
Topical minoxidil 5% solution applied to the affected scalp areas for 12 weeks.
Men will apply 1 cc twice daily and women will apply 1 cc once daily.
Three 2 mm punch biopsies will be obtained during the study: one from the balding scalp area and one from the non-balding scalp area at baseline, and one from the balding scalp area after 12 weeks of treatment.
Tissue samples obtained from scalp punch biopsies will be analyzed for Janus Kinase 2 (JAK2) protein levels using ELISA at baseline and after 12 weeks of treatment.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Baseline Difference in Tissue JAK2 Protein Levels Between Balding and Non-Balding Scalp
Tidsramme: Baseline
|
Comparison of tissue Janus Kinase 2 (JAK2) protein levels measured by ELISA in scalp biopsy specimens obtained at baseline from the balding area (vertex) and the non-balding area (occipital scalp) of participants with androgenetic alopecia.
|
Baseline
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Tissue JAK2 Protein Levels in Balding Scalp After 12 Weeks of Topical Minoxidil
Tidsramme: Baseline to Week 12
|
Change in tissue Janus Kinase 2 (JAK2) protein levels measured by ELISA in scalp biopsy specimens obtained from the balding scalp area at baseline and again after 12 weeks of topical minoxidil 5% treatment.
|
Baseline to Week 12
|
|
Change in Trichoscopic Hair Parameters After 12 Weeks of Treatment
Tidsramme: Baseline to Week 12
|
Change in trichoscopic parameters from baseline to Week 12, including hair density, terminal hair density, vellus hair density, average hair thickness, follicular unit density, percentage of single, double, and triple-or-more hairs per follicular unit, and average number of hairs per follicular unit.
|
Baseline to Week 12
|
|
Correlation Between Change in Tissue JAK2 Levels and Clinical Response
Tidsramme: Week 12
|
Correlation between the change in tissue JAK2 protein levels after treatment and the degree of clinical improvement assessed by trichoscopic parameters and baseline clinical characteristics.
|
Week 12
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. februar 2026
Primær færdiggørelse (Anslået)
1. oktober 2026
Studieafslutning (Anslået)
1. januar 2027
Datoer for studieregistrering
Først indsendt
25. april 2026
Først indsendt, der opfyldte QC-kriterier
25. april 2026
Først opslået (Faktiske)
1. maj 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
1. maj 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
25. april 2026
Sidst verificeret
1. april 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- MS-655-2025
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
IPD-planbeskrivelse
Individual participant data (IPD) will not be shared because this is a single-center study with a small sample size, and de-identification cannot be fully guaranteed.
Aggregate results, including summary statistics and outcome analyses, will be made available through publication
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .